Neurofibromatosis 1 (NF1) is a common autosomal dominant disease with an estimated birth incidence of 1 in 2500. 1 The cardinal features of NF1 are café au lait spots, neurofibromas, iris Lisch nodules, and skinfold freckling. The diagnostic criteria were formulated by the National Institutes of Health Consensus Development Statement in 1988. 2 The complications are manifold, may aVect any of the body systems, and vary, even within the same family.
Neurofibromas are benign skin tumours arising from the connective tissue of nerve sheaths, especially the endoneurium. 3 They are composed predominantly of Schwann cells and fibroblasts, in addition to axons, perineurial cells, mast cells, and extracellular matrix. 4 They may be discrete dermal or nodular lesions or plexiform neurofibromas. Plexiform neurofibromas diVer from discrete neurofibromas because they have an expanded extracellular matrix, grow along the length of a nerve, and may involve multiple fascicles and branches. They interdigitate with surrounding structures, often resulting in diVuse hypertrophy of bone and soft tissues. Superficially visible plexiform neurofibromas were reported in 26.7% of patients with NF1 in one population based study. 1 In a recent study, Tonsgard et al 5 performed CT on 91 adults with NF1 and found that 20% had plexiform neurofibromas in the chest and 40% in the abdomen or pelvis. Plexiform neurofibromas are a potent cause of disfigurement, impaired function, and emotional distress. However, the growth characteristics of these lesions have not been determined and periods of rapid growth may be followed by relative quiescence. About 4% of patients with NF1 develop malignant peripheral nerve sheath tumours which arise within plexiform neurofibromas and often carry a poor prognosis. 6 The tumours may metastasise to the lung, brain, liver, bone, soft tissue, regional lymph nodes, skin, and retroperitoneum. 7 Optimal management is dependent on early and accurate histological grading and staging of the disease, but malignant peripheral nerve sheath tumours are often diYcult to detect and may metastasise to many diVerent sites. Pain, rapid increase in the size of a neurofibroma, and the development of neurological deficit are clinical indicators of malignancy, but may also be features of benign plexiform neurofibromas. Magnetic resonance imaging locates the site and extent of the plexiform neurofibroma but is not reliable in detecting malignant change. 8 Malignant peripheral nerve sheath tumours often contain heterogeneous areas, biopsy of a small part of the lesion does not always reflect the overall character of the tumour, and high grade areas may be missed. In this study, we evaluated the ability of 18 FDG PET to detect malignant peripheral nerve sheath tumours, arising from plexiform neurofibromas in patients with NF1.
Methods
The patients were recruited between 1996 and 1998 from our multidisciplinary neurofibromatosis clinic and comprised 400 patients.
Overall, 35% of our patients have plexiform neurofibromas. A clinical and neurological examination was carried out on patients reporting pain, increased size, or neurological deficit in a plexiform neurofibroma. We report our experience with the first 18 patients.
MRI
Magnetic resonance imaging was performed on 18 patients with a 1.5 Tesla superconducting system (Philips Gyroscan S15, Philips Medical Systems). Images were taken in the axial and coronal planes with a slice thickness of 5 mm and an interscan distance of 0.5 mm. Coronal STIR images (TR/TE 2000/25, TI 150) were performed and axial T1 images (TR/TE 700/20) were carried out before and after the administration of gadoliniummeglumine-triaminepentacetic acid contrast medium at 0.2 ml/kg.
18
FDG PET PROTOCOL Imaging was carried out on all patients after a 6 hour fast. Localised imaging of the mass was performed in all patients and whole body or half body scans were carried out on seven patients. Data were acquired using an ECAT 951R whole body system (Siemens/CTI, Knoxville, TN, USA). The scanner has an image resolution of about 8 mm and an axial field view of 10.8 cm (one bed position equalled 10.8 cm). A whole body scan (not corrected for attenuation) was performed for 5 minutes per bed position, about 60 minutes after intravenous injection of 350 Mbq 18 FDG. Localised attenuation corrected views of the mass were undertaken after the whole body study, if this was performed, using a combined protocol of a 10 minute transmission scan and a 15 minute emission scan. This allowed a semiquantitative calculation of the rate of 18 FDG metabolism in the tumour to be made. The images were displayed as coronal, sagittal, and transaxial sections. FDG uptake which is related to the regional metabolic rate of glucose, provided that the uptake of the tracer into the tumour has reached its maximum value.
QUALITATIVE ASSESSMENT Qualitative assessment was made by a senior nuclear medicine physician experienced in PET with the specific aim of establishing if the mass was benign or malignant. In addition, the distribution of the uptake of 18 FDG within the tumours was noted. Patients who had symptoms and neurological deficit which could have arisen from more than one site, underwent whole or half body scans. In those patients, the 18 FDG uptake by the tumour was compared with the liver, and those tumours with uptake greater than the liver were deemed to be malignant.
QUANTITATIVE ASSESSMENT
Quantitative assessment was made by the calculation of the SUV (see equation
where Atumour is the tumour activity concentration (MBq ml[-1]), ID is the injected dose of FDG (MBq), BW is the body weight (g) and P is an experimentally determined partial volume correction. The SUV as a function of time, SUV(t), was calculated according to equation 2:
where C(t) is the activity concentration at time t measured using a 4.5 mm circular region of interest, A is the injected activity, M is the body mass, and G is a simple glucose correction factor (blood glucose concentration/4.5 mmol l -1 ). The SUV time was the time after the injection when the SUV the transmission/emission scan was performed.
All scans were reported blind, without knowledge of any other imaging modality that had been undertaken of the tumour of concern and before a definitive histological diagnosis of the mass.
HISTOLOGY
The histological diagnosis and grading of the tumour was performed using the criteria of tumour diVerentiation, necrosis, and the mitotic count to determine whether the tumour was low, intermediate, or high grade. 16 
STATISTICAL ANALYSIS
The SUV results for malignant and benign tumours were compared with the MannWhitney U test and two tailed p values have been quoted. 
Results
Between 1996 and 1998, 10 females and eight males with NF1 presented with pain, enlargement, or neurological deficit associated with a plexiform neurofibroma (table 1). The median age of the patients was 23.5 years with an age range of 12-62 years. Twenty three lesions were detected on MRI and four patients had more than one plexiform neurofibroma. Sixteen plexiform neurofibromas were visible in the limbs, eight proximally and eight distally, one was identified on MRI in the brachial plexus (figs 1 and 2), two were detected in the neck and four in the trunk. Pain persisting for more than 1 month and interfering with daily activities, was a feature in 17 from 23 tumours. Increase in size was present in 19 of 19 visible tumours. Neurological deficit was present in 14 of 23 tumours.
Five patients with NF1 had seven malignant peripheral nerve sheath tumours and histological examination showed four high grade and three low grade tumours. Three of the high grade tumours were triton tumours exhibiting rhabdomyoblastic features (table 2, cases 2-5). The median age of these patients was 23 years with an age range of 17-62 years. One patient had severe pain (waking her from sleep) and neurological deficit caused by a prevertebral plexiform neurofibroma at the level of L1 and 18 FDG PET indicated that the lesion was malignant (case 1). However, biopsy was technically diYcult as the lesion was in close proximity to the aorta and it was not possible to confirm the diagnosis histologically.
Fifteen benign plexiform neurofibromas were diagnosed in 12 patients with NF1 and histology confirmed the findings in four patients (cases 7, 8, 13, and 15, table 2). The median age of patients with benign plexiform neurofibromas was 30.5 years with an age range of 12-35 years.
FDG PET: QUALITATIVE ASSESSMENT
The radiologist assessed 23 plexiform neurofibromas from 18 patients and on visual inspection reported 13 plexiform neurofibromas as benign and 10 as malignant. No malignant tumours were classified as benign, but two benign tumours were rated as malignant (cases 7 and 8). Histology was not diagnostic in one plexiform neurofibroma which was deemed to be malignant (case 1).
FDG PET: QUANTITATIVE ASSESSMENT
The SUV was calculated in 20 tumours (table  2, fig 3) . The mean SUV for five malignant tumours was 5.4 (SD 2.4), range 2.7-8.4, which was significantly higher than the SUV for 15 benign tumours, which was 1.54 (SD 0.7,) range 0.56-3.3 (Mann-Whitney U test=1.5, p (two tailed) 0.002 (case 1 excluded from the analysis)).
The mean time after 18 FDG injection to when the SUV was calculated for 20 tumours was 111 minutes, median 105.5 minutes, range 45-206 minutes (case 1 excluded). The mean SUV time for five malignant peripheral nerve sheath tumours was 108 minutes, median 90 3 and 4) . Three patients are currently asymptomatic 5 months after surgery (case 5), 12 months after surgery (case 6), and 26 months after surgery and radiotherapy (case 2). The patient with a prevertebral plexiform neurofibroma at L1 and inconclusive histology has persistent symptoms of pain and neurological deficit 9 months after presentation.
Five plexiform neurofibromas were excised in four patients and were benign. These patients have remained asymptomatic 15 months, 3 months, 10 months, and 26 months after surgery (cases 7, 8, 13, and 15). Eight patients with 10 plexiform neurofibromas which were thought to be benign on 18 FDG PET did not undergo surgery, either because the patient refused surgery or the risk of morbidity was too high. They were followed up for 3 to 26 months after presentation (median 9 months). Four of these patients originally presented with pain arising from a plexiform neurofibroma (cases 9, 10, 12, and 17). On follow up, the pain had resolved in all patients except patient 10 who experienced aching in her leg after prolonged standing at work. All patients had reported an increase in size of the plexiform neurofibroma on presentation. Subsequently, six patients reported no further change in size, one patient reported a decrease in size (case 17), and in one case the lesion was in the pelvis and not visible to the patient (case 14). Four patients presented with neurological deficit (cases 12,14,16, and 18) and the deficit remained unchanged on follow up (table 3) .
Discussion
Qualitative assessment identified all the malignant tumours but yielded false positive results in two lesions. Quantitative assessment showed a significant diVerence in mean SUV between benign and malignant lesions. However, fig 3 shows an overlap between benign and malignant lesions between SUV 2.7 and 3.3. A cut oV of 2.5 for the SUV would yield only one false positive result. Cases 3 and 4 were incorrectly thought to have malignant lesions and in these cases the SUV was calculated at 45-60 minutes after
